Related Experiment Videos
Sirolimus: a ten-year perspective
1Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School, Houston, Texas, USA.
Transplantation Proceedings
|March 12, 2004
Summary
Sirolimus, an immunosuppressive drug, effectively reduces kidney transplant rejection when combined with cyclosporine and steroids. Early withdrawal of cyclosporine may improve long-term renal function while maintaining immunosuppression.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Sirolimus is a critical-dose immunosuppressive macrocyclic lactone.
- Therapeutic drug monitoring is essential for sirolimus efficacy.
- Novel immunosuppressive mechanism requires careful clinical evaluation.
Purpose of the Study:
- Evaluate sirolimus in combination therapy for kidney transplant recipients.
- Assess the impact of sirolimus on acute rejection episodes.
- Investigate long-term renal function benefits and potential adverse effects.
Main Methods:
- Two multicenter, blinded clinical trials were conducted.
- Sirolimus was compared with azathioprine or placebo.
- Cyclosporine withdrawal protocols were implemented in some patient groups.
Main Results:
- Sirolimus combined with cyclosporine and steroids reduced acute rejection episodes.
- Chronic sirolimus therapy showed long-term renal function benefits after cyclosporine withdrawal.
- Sirolimus use was associated with hypertriglyceridemia, hypercholesterolemia, and myelosuppression.
Conclusions:
- Sirolimus-cyclosporine combination allows for early steroid withdrawal post-transplant with low rejection rates.
- Sirolimus demonstrates potential in calcineurin antagonist-free regimens due to lack of nephrotoxicity.
- Careful monitoring for metabolic and hematologic side effects is crucial with sirolimus therapy.